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ABSTRACT-The biocarbon ureterostomy device is a stoma1 prosthesis for upper tract urinary 
diversion that has had preliminary successes in animal and human trials in Europe and Peru. Im- 
plantation of a pure carbon stoma1 prosthesis offers the potential advantages of high biocompatibil- 
ity, lack of encrustation, and elimination of stoma1 stenosis which is frequently associated with 
cutaneous ureterostomy. Nine biocarbon ureterostomy devices were implanted from August, 1984 
through July, 1985. Although successful implantation was achieved in 2 patients, the complication 
rate was high. The biocarbon ureterostomy device has potential as an alternative form of urinary 
diversion. However, significant problems need to be remedied before it can be recommended for 
routine clinical application. 
The variety of urinary diversions currently in 
use by urologists are testimony to the absence of 
a simple, reliable procedure. Because of this, 
we have evaluated a vitreous carbon prosthesis 
for cutaneous ureterostomy in 9 patients re- 
quiring urinary diversion. Pure carbon in the 
vitreous or glassy form was first developed and 
characterized in England in 1963 as an out- 
growth of space exploration. The remarkable 
characteristics of this pure carbon material sug- 
gested its potential biologic applicability. Vitre- 
ous carbon is a hard, impermeable solid that is 
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chemically inert at ambient temperature and 
shows no galvanic activity with saline solu- 
tions. ’ 
Mooney, Hartmann, and McNeal’ used a 
pure carbon percutaneous electrical connector 
and found it to be biologically inert and free of 
infection for more than two years. Longley and 
associates2 evaluated a vitreous carbon uros- 
tomy device for vesicostomy and ileal bladder 
stomata in dogs and documented its feasibility 
by demonstrating good short-term function. 
Harzmann, Bichler, and Ideler3 reported the 
successful use of biocarbon urinary conduits for 
vesicostomy stomata in 6 patients for up to fif- 
teen months. The stomas resulted in urinary 
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continence without encrustation and with good 
wound healing. B A carbon prosthesis was also 
evaluated in several animal species as a stoma1 
device for ureterocutaneous anastomoses.4 A 
functioning conduit was obtained in 7i percent 
of the implants. Eleven of 48 stoma1 prostheses 
were unsuccessful. Causes of stoma1 failure in- 
cluded poor healing, parastomal inflammation, 
urinary extravasation, and severe encrustation. 
Pow-Sang and associates5 implanted bicar- 
bon ureterostomy devices in 20 patients with 
uterine cervical or bladder cancer. Only 1 pa- 
tient was alive at the time of the report. She had 
a functioning implant at one year after two 
reimplants. Of the remaining patients, 18 died 
of carcinomatosis and 1 had a cardiac arrest 
eleven days postoperatively. Eleven implants 
were functioning at the time of death. Urinary 
fistulas developed in 7 patients. 
A clinical trial with a biocarbon ureteros- 
tomy prosthesis was begun in the United States 
in 1984. Results of this trial are reported. 
Material and Methods 
Vitreous (glassy) carbon is the primary com- 
ponent of the biocarbon ureterostomy device. 
It is composed of 99.9 percent pure carbon, and 
its hardness and impermeability enable it to ac- 
cept a high surface polish. The biocarbon ure- 
terostomy device is a rigid, transcutaneous pros- 
thesis providing a nonstenosing route for urine 
drainage from the ureters. The device has a ta- 
pered inner spout with an internal circum- 
ference of 11.5 F that can be intubated into the 
ureter. The larger outer spout has a rim to facil- 
itate a leak-free attachment to a drainage 
device. In addition there is a wide flange in the 
device which is inserted between the abdominal 
muscle and external fascia for fixation. The in- 
ner spout is covered with Dacron fabric to pro- 
mote tissue ingrowth (Fig. 1). 
Nine people received biocarbon implants 
from August 30, 1984 to July 17, 1985. Seven 
were implanted with devices with a straight in- 
ner spout, and two were implanted with 
devices with a curved inner spout. Indications 
for the devices included cystectomy or ureteral 
obstruction. Transureteroureterostomy was per- 
formed in the 5 patients who had cystectomy. 
An indwelling single J ureteral stent through 
the conduit was routinely employed for up to 
six weeks after the implantation. Postopera- 
tively, the patients were followed closely and 
were specifically monitored for infection, en- 
crustation, urinary tract obstruction, fistula, 
FICUHE 1. BioCarbon uretrrostomy device consists 
of tapered. flanged. carbon tube with Dacron rcrap. 
and biocompatibility. Of the 4 patients who 
died of their cancer, postmortern examination 
of the biocarbon device was not possible in 2. 
All five devices removed for infection and fis- 
tula underwent pathologic examination. 
Results 
Nine patients with a mean age of sixty-four 
years (range 56 to 71 years) underwent single 
biocarbon ureterostomy implantation. Indica- 
tions for the device included cystectomy for 
bladder cancer (5), unilateral obstruction of the 
ureter (2), and stenosis of a previous cutaneous 
ureterostomy (2). The 5 cystectom!, patients all 
had transureteroureterostomy at the time of 
surgery. The mean and median duration of im- 
plantation was one hundred thirty days and 
seventy-six days, respectively. A summary of the 
results is listed in Table I. 
Two patients (LB and WE) died of neoplastic 
disease with functioning devices. The duration 
of device implantation in these individuals was 
thirty-four and one hundred seventy three days. 
Their devices were not retrieved for examina- 
tion. Two other patients died of neoplasm but 
had complications with their dcavices. One 
(WR) had a satisfactorily functioning device. 
However, for the last two weeks of his life as- 
citic fluid leaked around the device requiring 
the use of a urostomy bag over the prosthesis. In 
the other patient (VL) progressive hydrone- 
phrosis developed secondary to lymphocele ob- 
struction which was drained six months after 
implantation. A sinus near the ureterostomy 
device started leaking urine six and one-half 
months after implantation and was managed 
by his wearing a urostomy bag over the device 
for the last five months of his life. 
In the remaining 5 patients, the device was 
removed because of device-related complica- 
tions and urinary diversion was accomplished 
by other means (4 ileal conduits and 1 cuta- 
neous ureterostomy). Three devices were re- 
moved because of urinary fistulas. One patient 
(FJ) had a device implanted into a stenosed cu- 
taneous ureterostomy. The device was subse- 
quently removed because of ureteral obstruc- 
tion proximal to the device and Pseudomonas 
skin infection around the prosthesis. One pa- 
tient (LC) had an excess of subcutaneous adi- 
pose tissue which was partially excised at the 
time of his implantation. Nevertheless, the 
device subsequently retracted below the skin 
level followed by the development of soft tissue 
infection requiring removal of the prosthesis. 
Primary problems were the development of 
urinary fistulas and soft tissue infections caused 
by a variety of organisms. Inadequate spout 
length of the device contributed to a poor result 
in at least 1 patient (LC). Adequate ingrowth of 
tissue into the Dacron sheath was generally 
poor in the devices that were examined (Fig. 2). 
However, the successful devices were not re- 
FIGURE 2. Zone of attachment of ureter to inner 
uxap Dacron is show>n in device explanted after six 
weeks. Urothelium is marked by arrow. Little colla- 
gen in Dacron inner wrap material. (Masson tri- 
chrome stain.) 
trieved for follow-up study. An additional tech- 
nical concern was the development of signifi- 
cant encrustation clogging the indwelling single 
J ureteral stent in 2 patients. 
TARLE I. Results of biocarbon implantation 
Implant 
Patient Age Indication Duration Outcome 
BM 63 Cystectomy 83 Removed-urinary fistula 
VL 63 Cystectomy 391 Cancer death-urine leak managed 
by urostomy bag for five months 
LB 62 Cystectomy 173 
FJ 70 Stenotic cutaneous 
Cancer death-successful implant 
40 Removed-ureteral obstruction 
ureterostomy and infection 
WE 71 Ureteral obstr. 34 
HH 67 Cystectomy 




69 Cystectom! 76 Removed-infection, short device 
WR 58 Ureteral obstr. 70 Cancer death-good function 
BT 56 Stenotic cutaneous 
(late leakage of ascitic fluid) 
260 Removed-urinary fistula 
ureterostomy 
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Comment 
Despite the recent trend toward continent 
urinar!. diversions, most urinary diversions still 
require the use of an external collection bag. 
Furthermore, virtuallv all urinary diversions 
require the use of portions of the small and/or 
large intestine. Cutaneous ureterostomv is one 
of the few upper tract alternatives for a tubeless 
external diversion that is simple and does not 
require a bowel anastomosis. However, cuta- 
neous ureterostomy is not without its complica- 
tions. The small size of unobstructed ureters re- 
sults in a high incidence of stoma1 stenosis. 
Because of this, enthusiasm for this form of 
diversion is low. Nevertheless, the relative sin- 
plicity of this procedure has prompted Bracken 
and Kinder” to advocate intubated cutaneous 
ureterostomy for individuals in poor health 
with normal-sized ureters who require cystec- 
tomy. 
Vitreous carbon is biologically and chemi- 
cally inert and has been clinically effective as a 
material for long-term vascular access.’ Because 
of these attributes, we tested a ureterostomy 
device constructed of biocarbon. Theoretical 
advantages include (1) a short, simple proce- 
dure, (2) no sacrifice of a bowel segment, (3) no 
stoma1 stenosis, and (4) an easily managed ex- 
ternal appliance. Although successful device 
implantation was accomplished in 2 patients, a 
high complication rate was noted. Urinary fis- 
tulas and soft tissue infections around the device 
were common. Furthermore, a high incidence 
of poor tissue ingrowth into the Dacron cov- 
ering the biocarbon was noted. Whether these 
represent separate events or are a consequence 
of one another is unclear. Infections not only 
may have an adverse effect on wound healing 
but also may increase the stone-forming ability 
of urine. Despite the high degree of inertness of 
biocarbon, encrustation was noted on two 
devices. In both cases, the sediments were noted 
near the tip of the biocarbon device and were 
easily removed with a cotton swab. Mechanical 
problems included devices that were too short 
for obese patients and the potential for kinking 
of the ureter at the junction of the device. The 
role of an indwelling stent in device success or 
failure could not be determined. In at least 1 
case, obstruction by the stent may have contrib- 
uted to a urinary fistula and device failure. 
Although this clinical trial was not without 
its successes, the demonstrated hazards of the 
implantable vitreous carbon ureterostom? 
device in its present form and yvith the opera- 
tive technique employed argue against further 
clinical investigation without significant 
changes. Urine creates an unfriendly entriron- 
ment for any prosthesis, no matter how inert. 
This is well demonstrated by the concretions 
noted on silicone ureteral catheters. BioCarbon 
was remarkably resistant to this problem but 
did not obviate it completely. More important, 
perhaps, is the difficulty we ha.d in achieving 
good tissue ingrowth into the prosthesis. The 
carbon is nonporous and does not bind to tissue. 
The Dacron outer covering in its present form 
achieved adequate tissue ingrowth for device 
fixation but did not accomplish a urine-tight 
seal. A simple nonintubated, stenotic-free pros- 
thesis for cutaneous ureterostomy would be a 
welcome addition to the urologist’s armamen- 
tarium. Additional work is required before such 
a device can be recommended. 
Section of Urolog. 
1500 E. Medical Center Drive 
Ann Arbor. Michigan 38109-0330 
(DR. GROSSMAN) 
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